On June 12, 2025, HCW Biologics Inc. reported that Armistice Capital exercised pre-funded warrants to purchase 85,000 shares of its common stock, following earlier exercises for a total of 374,140 shares. Armistice still holds warrants for an additional 54,000 shares.